Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.

Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH

Bone6 Jan 2010Cited by 35 (Europe PMC)

PMID20060081DOI10.1016/j.bone.2009.12.032PepBankPUB-20060081

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In teriparatide-treated patients with glucocorticoid-induced osteoporosis, baseline bone turnover markers were not significantly linked to lumbar spine BMD gains.
In plain wordsIn teriparatide-treated patients, baseline bone markers were not significantly linked to spine bone density gains.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBaseline markers and lumbar spine BMD response
Study
n = 80
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the teriparatide group, increases in LS and FN BMD at 18 months were not significantly correlated with baseline marker concentrations (P>0.05) but were correlated with the increases in PINP at 1 and 6 months (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this post hoc analysis was to determine whether baseline concentrations or early changes in serum bone turnover markers were correlated with changes in bone mineral density (BMD) at 18 months in patients with glucocorticoid-induced osteoporosis (GIO) treated with teriparatide (n=80; 2…
Summary · context
The relationship between baseline and early changes in markers and the 18-month changes in lumbar spine (LS) and femoral neck (FN) BMD was evaluated using Spearman correlation analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2006008101
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In teriparatide-treated patients with glucocorticoid-induced osteoporosis, baseline bone turnover markers were not significantly linked to femoral neck BMD gains.
In plain wordsIn teriparatide-treated patients, baseline bone markers were not significantly linked to femoral neck bone density gains.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBaseline markers and femoral neck BMD response
Study
n = 80
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the teriparatide group, increases in LS and FN BMD at 18 months were not significantly correlated with baseline marker concentrations (P>0.05) but were correlated with the increases in PINP at 1 and 6 months (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this post hoc analysis was to determine whether baseline concentrations or early changes in serum bone turnover markers were correlated with changes in bone mineral density (BMD) at 18 months in patients with glucocorticoid-induced osteoporosis (GIO) treated with teriparatide (n=80; 2…
Summary · context
The relationship between baseline and early changes in markers and the 18-month changes in lumbar spine (LS) and femoral neck (FN) BMD was evaluated using Spearman correlation analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2006008102
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In teriparatide-treated patients, PINP increases at 1 and 6 months were linked to lumbar spine BMD increases at 18 months.
In plain wordsIn teriparatide-treated patients, early PINP increases were linked to later spine bone density increases.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP changes and lumbar spine BMD response
Study
n = 80
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the teriparatide group, increases in LS and FN BMD at 18 months were not significantly correlated with baseline marker concentrations (P>0.05) but were correlated with the increases in PINP at 1 and 6 months (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this post hoc analysis was to determine whether baseline concentrations or early changes in serum bone turnover markers were correlated with changes in bone mineral density (BMD) at 18 months in patients with glucocorticoid-induced osteoporosis (GIO) treated with teriparatide (n=80; 2…
Summary · context
The relationship between baseline and early changes in markers and the 18-month changes in lumbar spine (LS) and femoral neck (FN) BMD was evaluated using Spearman correlation analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2006008103
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In teriparatide-treated patients, PINP increases at 1 and 6 months were linked to femoral neck BMD increases at 18 months.
In plain wordsIn teriparatide-treated patients, early PINP increases were linked to later femoral neck bone density increases.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP changes and femoral neck BMD response
Study
n = 80
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the teriparatide group, increases in LS and FN BMD at 18 months were not significantly correlated with baseline marker concentrations (P>0.05) but were correlated with the increases in PINP at 1 and 6 months (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this post hoc analysis was to determine whether baseline concentrations or early changes in serum bone turnover markers were correlated with changes in bone mineral density (BMD) at 18 months in patients with glucocorticoid-induced osteoporosis (GIO) treated with teriparatide (n=80; 2…
Summary · context
The relationship between baseline and early changes in markers and the 18-month changes in lumbar spine (LS) and femoral neck (FN) BMD was evaluated using Spearman correlation analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2006008104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.